Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Fortress Biotech (FBIO) over the last 13 years, with Q3 2025 value amounting to $86.2 million.

  • Fortress Biotech's Cash & Equivalents rose 4649.72% to $86.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $86.2 million, marking a year-over-year increase of 4649.72%. This contributed to the annual value of $57.3 million for FY2024, which is 2924.12% down from last year.
  • Per Fortress Biotech's latest filing, its Cash & Equivalents stood at $86.2 million for Q3 2025, which was up 4649.72% from $74.4 million recorded in Q2 2025.
  • Fortress Biotech's 5-year Cash & Equivalents high stood at $305.7 million for Q4 2021, and its period low was $57.3 million during Q4 2024.
  • For the 5-year period, Fortress Biotech's Cash & Equivalents averaged around $155.7 million, with its median value being $91.3 million (2025).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first surged by 11324.89% in 2021, then crashed by 6863.7% in 2023.
  • Fortress Biotech's Cash & Equivalents (Quarter) stood at $305.7 million in 2021, then plummeted by 41.69% to $178.3 million in 2022, then crashed by 54.6% to $80.9 million in 2023, then dropped by 29.24% to $57.3 million in 2024, then surged by 50.56% to $86.2 million in 2025.
  • Its Cash & Equivalents was $86.2 million in Q3 2025, compared to $74.4 million in Q2 2025 and $91.3 million in Q1 2025.